Recent Advances and Future Directions in the Management of HER2+ Gastric Cancer
An expert in gastric cancers provides insight on the recent advances and future directions for the management of locally advanced and metastatic gastric cancers.
The DESTINY-Gastric-01 Trial
Dr John Marshall discuss the DESTINY-Gastric01 trial and the implications of the study results to clinical practice for HER2+ metastatic gastric cancer.
Second- and Later Line Treatment Options for Metastatic HER2+ Gastric Cancer
John Marshall, MD, reviews options for second- and later line therapies and considerations for treatment sequencing in patients with HER2+ gastric cancers.
Frontline Treatment in Metastatic HER2+ Gastric Cancer
Dr John Marshall discusses frontline systemic treatment options for metastatic HER2+ gastroesophageal junction cancer and gastric cancer in general.
Molecular Testing for Metastatic HER2+ Gastric Cancer
An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.
Case Presentation: Metastatic HER2+ Gastric Cancer
John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.
Dr. John Marshall on Individualizing Treatment for Patients With Colorectal Cancer
John Marshall, MD, discusses the individualization of treatment of patients with colorectal cancer (CRC).